BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors July 17, 2019 0
Discovery of mechanism behind precision cancer drug opens door for more targeted treatment July 8, 2019
Cyteir Therapeutics announces new data demonstrating lead compound CYT-0851 is active against lymphomas & solid tumors, synergistic with PARP inhibitors March 31, 2019
Enzyme USP15 may have potential role in future treatment of various cancers (See original publication below) March 15, 2019